Indeed adding CpG to our N+LT neonatal vaccine not only reduced the Th2 bias of the recall response to a boost with N (less IL-5, more IgG2a), but also abrogated eosinophilia following an RSV challenge, as assessed in BAL cells. The gene discussed is IL5; the disease is Increased total eosinophil count.